Fangda Partners houses ‘a highly competent team of life sciences and healthcare lawyers’, who are equipped to handle ‘the whole life cycle of life sciences and health products’. Highly praised for its ability to ‘combine expertise from many practice areas within the firm’, the practice assists a stellar list of clients with financings, rights issuances, regulatory compliance, licensing applications, IP disputes, and antitrust matters. With ‘many years of experience in the biomedical industry’, Shanghai-based Josh Shin regularly advises on distribution and collaboration agreements. In Beijing, Kate Yin focuses on regulatory compliance and enforcement actions while Fang Qi handles IP transactions and antitrust litigation. M&A, foreign investment and PE matters are the area of expertise of Shanghai-based Diana Li. Splitting his time between Beijing and Hong Kong, Michael Han is recommended for joint ventures and antitrust investigations. Sherry Yao departed in April 2022.
Life sciences and healthcare: PRC firms in China
Josh Shin; Kate Yin; Michael Han; Fang Qi
Other key lawyers:
Yiren Hu; Gil Zhang
‘They work as a very strong team with exceptional depth in expertise and breadth of work scope. The team has an excellent business sense besides their outstanding legal skills.’
‘Josh Shin has very good business sense and is always on top of all matters. Yiren Hu is very detail oriented and skilled in cross-border transactions.’
‘Fangda has a highly competent team of life sciences and healthcare lawyers. The practice covers legal services related to the whole life cycle of life sciences and health products. They provide our company with multi-faceted and multi-dimensional legal advice such as BD, clinical, listing access, advertising, antitrust, data and personal information protection.’
‘Diana Li has a thorough understanding of and many years of experience in the life sciences and healthcare industry, with a with a deep understanding of new technologies and products.’
‘Fangda’s life sciences and healthcare team is able to combine expertise from many practice areas within the firm to provide comprehensive high-quality legal services.’
‘Josh Shin is a distinguished partner in Fangda’s life sciences and healthcare team. He is able to quickly understand the company’s business model and provide timely high-quality advice.’
‘Josh Shin has many years of experience in the biomedical industry, being familiar with professional investors and start-up companies operating in the industry.’
‘Josh Shi and Gil Zhang have good understanding of the client business model and the complex regulatory framework which impacts the client’s business.’
Yunfeng Fund II
Everbright Healthcare Fund
Shanghai Kehua Bioengineering
EdiGene Beijing Biotechnology
LifeTech Scientific Corporation
Wuxi JW Therapeutics
CICC Healthcare Fund
Johnson & Johnson
Smith & Nephew
Smith & Nephew
CMS (China Medical System)
AZ-CICC Healthcare Fund
Beijing Naton Technology
- Advised BeiGene on its $3.5bn (before over-allotment option is fully exercised) initial public offering and listing on the STAR Market Shanghai, after acting for BeiGene as the company PRC counsel on its IPOs on NASDAQ and HKEX.
- Assisted CStone Pharmaceuticals in granting exclusive rights to Hengrui Pharmaceuticals for research, development, registration, manufacturing, and commercialisation of anti-CTLA-4 mAb CS1002 in the Greater China region.
- Acted for MediTrust Health on its Series-C financing co-lead by Boyu Capital and Janchor Partners, involving an aggregate financing amount of over ¥2bn.
The dedicated life science and healthcare team at Global Law Office is rated for its ‘strong and longstanding reputation in the market’ and its full-service offering, which includes M&A, investment transactions, licensing matters, IP, regulatory compliance and litigation. In addition to acting for high-profile pharmaceutical companies such as Johnson & Johnson and AstraZeneca, the practice is often sought after by industry associations and government bodies to assist with policy and regulatory matters. The team is jointly led by ‘distinguished partner’ Alan Zhou, who has extensive experience in advising on private equity and venture capital transactions, and M&A and foreign investment specialist Michael Yu, from Shanghai and Beijing, respectively. Jerry Liumatters focuses on corporate and cross-border M&A matters while Charlene Huang is a key contact for licence deals and outbound and inbound investment. Coco Fan and Jacky Li are recommended for regulatory compliance and antitrust investigations.
Alan Zhou; Michael Yu
Other key lawyers:
Jerry Liu; Coco Fan; Charlene Huang; Jack Li
‘Alan Zhou and Coco Fan are very knowledgeable about the pharmaceutical industry, professional and efficient.’
‘Global’s life science and healthcare team has a strong and longstanding reputation in the market. The firm’s in-depth insight into the industry and close connection with legislators are impressive.’
‘Alan Zhou has many years of experience in the industry and his extensive network in the pharmaceutical industry provides a rare opportunity for pharmaceutical companies to participate deeply in relevant legislative discussions.’
‘Very knowledgeable about the pharmaceutical industry, professional and efficient.’
‘Global Law Office is intimately familiar with the life sciences and healthcare sector, and its advice to clients is very pragmatic and innovative. Its lawyers have been in the field for many years and have a deep understanding of the legal, compliance, data protection and IP matters related to the healthcare industry.’
‘Alan Zhou is a distinguished partner with extensive experience in life sciences and healthcare legal and compliance matters. He is good at communicating with clients, understanding client needs, and proposing pragmatic and business-orientated solutions.’
‘Alan Zhou has extensive knowledge of the industry and provides good advice in line with market practices.’
Johnson & Johnson
- Acted for Primavera Capital on the $2.2bn acquisition of Mead Johnson from Reckitt Benckiser Group’s Greater China Business.
- Assisted Jemincare in co-operating with Orion on a new non-opioid analgesic drug, a project valued at $489m.
- Represented AstraZeneca in its patent infringement litigation appeal proceedings before the Supreme People’s Court against generic manufacturer Jiangsu Aosaikang Pharmaceutical Co., Ltd.
King & Wood Mallesons
With ‘extensive knowledge of investment, licence registration, compliance, and antitrust matters’, the healthcare & pharmaceuticals team at King & Wood Mallesons is ‘on top of key developments and trends in the industry, offering tailored and creative solutions’. Acting for a wide range of clients, including health insurance groups, private equity houses, investors, biotech companies and hospitals, the practice enjoys the ability to leverage the firm’s international network, which makes it well placed to handle cross-border matters. Leading the team from Beijing is Jianwen Huang, who specialises in inbound and outbound investment and M&A mandates. Tina Tai and Wenping Chen are recommended for IP matters, enforcement actions and investigations while Yuanyuan Zhu is a key name for compliance matters and investigations. In Shanghai, Mark Zhang and Fan Yang handle cross-border investment, M&A and PE matters. Also noted are Shenzhen-based Ting Liu and senior associate Lingbi Li in Shanghai.
Other key lawyers:
Tina Tai; Wenping Chen; Mark Zhang; Ting Liu, Fan Wang; Yuanyuan Zhu; Lingbi Li
‘The firm provides a full range of services and has extensive knowledge of investment, licence registration, compliance, and antitrust matters.’
‘Mark Zhang is an excellent and very professional lawyer, who gives appropriate advice that matches the needs of the client’s business.’
‘King & Wood Mallesons is one of the few law firms in China with a dedicated healthcare team, with deep legal expertise and extensive transactional experience. The team also includes senior lawyers with biomedical background.’
HUTCHMED (China) Limited
CANbridge Pharmaceuticals Inc
Reckitt Global and Reckitt Benckiser (China) Investment Co., Ltd
Beijing Leto Laboratories Biotechnology Co., Ltd
RemeGen Co., Ltd
Harbin Pharmaceutical Group
- Advised RemeGen Co., Ltd on its initial public offering of A-shares on the STAR market of the Shanghai Stock Exchange.
- Acted for Beijing Leto Laboratories Biotechnology Co., Ltd on a joint development agreement with Hanson Pharmaceutical Group Company Limited.
- Represented Novartis AG in proceedings to maintain the validity of Entresto® compound patent.
With a deep bench of ‘experts from various fields, including drugs and medical device regulations, data protection and privacy, anti-bribery, antitrust and policy matters’, Zhong Lun Law Firm is equipped to assist clients with the whole chain of the life sciences and healthcare industry, from M&A and IPOs to IP matters and dispute resolution. The practice handles a heavy workload for large multinational pharmaceutical companies, medical groups and private equity firms. With ‘a strong background in biochemistry and pharmacy’, Helen Cheng ‘provides comprehensive legal advice, which covers joint ventures, cross-border transactions, compliance risk assessments, IP due diligence and disputes’. Yongbin Ge is a key contact for capital market matters and PE investment while Changyu Fu is especially sought after to assist clients with criminal litigation, arbitration proceedings and administrative disputes. Other key practitioners include Dongmei Wang, Jim Qiu, associates Qi Lan and IP expert Shuman Zhang.
Helen Cheng; Changyu Fu; Dongmei Wang; Yongbin Ge; Jim Qiu
Other key lawyers:
Yuru Zuo; Qi Lan; Shuman Zhang
‘Yuru Zuo offers comprehensive and timely advice that is suitable for the business needs of the client. In the face of unexpected changes, Zuo is professional, skilled and flexible.’
‘The team has a longstanding presence in the medical and healthcare sector, with extensive expertise in cross-border projects and the business operations of pharmaceutical companies.’
‘Helen Cheng has a strong background in biochemistry and pharmacy. He provides comprehensive legal advice, which covers joint ventures, cross-border transactions, compliance risk assessments, IP due diligence and disputes.’
‘Zhong Lun provides strong legal support in the research and development field, and the billing can be adjusted according to the needs of the client.’
‘The team is experienced, the lawyers are responsible and fees are reasonable. Very satisfied.’
‘The team includes legal experts from various fields and business areas, including drugs and medical device regulations, date protection and privacy, anti-bribery, antitrust, and policy matters, efficiently providing excellent results to clients.’
‘The team is responsive and provides advice in a timely manner.’
‘Jim Qiu understands our needs and always does his best to explore the best solutions. With extensive experience and insight into the life sciences industry, He always offers innovative and priceless advice. His team is unique and exceptional.’
Astellas Pharmaceutical(China)Co., Ltd
Baring Private Equity Asia
Beaufour-IPSEN (Tianjin) Pharmaceutical Co., Ltd
BeiGene Shanghai Biotechnology Co., Ltd
Beijing Jingdong Health Co., Ltd
China National Medicines Corporation Ltd
Eli Lilly and Company
Endeavour Consumer Health Limited
Exegenesis Bio, Inc.
Fosun Kite Biotechnology Co., Ltd
GlaxoSmithKline (China) Investment Co., Ltd
GlaxoSmithKline (China) R&D Co., Ltd
Global Health Drug Discovery Institute
Hong Kong Asia Medical Group
HOYA Lens Thailand Ltd
Lilly Asia Ventures
Mundipharma (China) Pharmaceutical Co, LTD
Nanjing Leads Biolabs Co., Ltd
Nestle (China) Ltd
PepsiCo Asia R&D Center Ltd
Pfizer Investment Co., Ltd
Shanghai ISO Medical Products Co. Ltd
Shanghai Pharmaceuticals Holding Co., Ltd
Shanghai Roche Pharmaceuticals Ltd
Shanghai SPH Ruier Drugs Co., Ltd
Shanghai Topcare Medical Services Co., Ltd
Stryker (Beijing) Healthcare Products Co., Ltd
The Management Office of All Shanghai Medical Associations
Vision Care, Hoya Group
Yantai Dongcheng Pharmaceutical Group Co., Ltd
- Assisted Hong Kong Asia Medical Group with its $400m series-D financing.
- Advised LianBio’s on its IPO on the Nasdaq Stock Market.
- Acted for Shanghai Topcare on the acquisition of Fullerton Healthcare Corporation Limited.
Han Kun Law Offices is highly rated for its ability to ‘assign a team with members from various departments to help with complex matters’. Acting for a varied client roster of pharmaceutical and healthcare companies, investment funds, and private equity and venture capital firms, the practice is recognised for its strong expertise in handling joint ventures, M&A, financial transactions and licensing deals. As part of its broad offering, the group also handles IP matters, regulatory compliance, antitrust issues and litigation. From Shanghai, ‘knowledgeable, patient and accessible’ Yinshi Cao, who focuses on private equity, venture capital and M&A, heads up the group while Min Zhu is recommended for foreign direct investment and corporate restructuring matters. In Beijing, Charles Li is a key contact for equity and debt financings and IP matters, and Aaron Zhou is noted for his expertise in cross-border M&A and licensing deals.
Other key lawyers:
Charles Li; Aaron Zhou; Min Zhu; Cheng Chen; Lijuan Wang
‘Professional and in-depth knowledge of the biotech industry. Fair price with engagement of counsels at all level.’
‘Min Zhu, Cheng Chen and Lijuan Wang are recommended.’
‘The team is extremely experienced in cross-border licensing deals. They are very patient to explain all the terms and potential consequences. They are highly efficient at summarising the arguments, making the entire contractual process extremely smooth. They are very collaborative and work very hard over weekends and countless nights. The final bill is very friendly.’
‘The lawyer in charge of the team is very knowledgeable, patient and accessible. Yinshi Cao can explain very complicated situations in an easy way. He thinks about all the potential risks to ensure the licensing deal goes smoothly. He knows how to persuade the other side to agree with his client.’
‘Great quality and thorough legal advice. Great negotiation skills that bring great value to the client.’
‘Min Zhu is really impressive.’
‘The team at Han Kun Law Offices is one of the best teams that we have worked with. The team is very accountable and experienced and always provides prompt and excellent support in complex transactions. The unique culture and structure of Han Kun Law Offices ensure it can assign a team with members from various departments to help us deal with complex matters. The team has superior commercial sense in providing solutions and constantly applies accurate commercial judgement to solve transaction obstacles. Lawyers are reachable at any time, including over the weekends, during holidays and in evenings.’
‘Aaron Zhou is very knowledgeable on healthcare-related transactions and possesses wonderful skills in dealing with tricky issues. Zhou is also a great negotiator and is very capable of drafting and negotiating in both English and Chinese, which is critical in cross-border transactions. Zhou has a very strong business sense and can always provide constructive solutions to help us close transactions. We are also impressed by his extremely strong responsiveness to our demands. I would not hesitant to reach out to him at any time, by phone or via email or WeChat.’
Innovent Biologics, Inc
- Advised Abogen Therapeutics on its $720m Series-C and $300m Series-C+ Financing.
- Acted for Wallaby Medical Holding, Inc on its approximately €500m acquisition of Phenox GmbH and Femtos GmbH.
- Assisted CVC with its strategic investment in Xi’an Yikang Pharmacy, a leading pharmaceutical retail chain in Northwest China with more than 1,600 pharmacies.
The Shanghai-based life sciences and healthcare team at JunHe LLP has a proven track record in handling large cross-border financial transactions such as IPOs and equity investments, M&A and PE and VC financing, which makes it a popular choice for multinational companies, investors, financial instructions, and PE firms. Xudong Tao is especially sough after by biotech and CRO companies to advise on domestic and Hong Kong’s capital markets products. Zoe Wang is recommended for IP matters and handling due diligence in pre-IPO stages. With more than 20 years of experience in representing clients in litigation and arbitration proceeding, Min Zhao is a key contact for disputes and corporate reorganisations. Corporate and M&A specialist Ning Liu, who regularly acts for Fortune 500 companies and major financial institutions, is another name to note.
Xudong Tao; Zoe Wang; James Zhu
Other key lawyers:
Ning Liu; Fangzhou Zhang; Yun Shi
‘JunHe’s life sciences team has supported our company with risk control matters and document review related to projects such as clinical trials for many years. It has always been well regarded by our company. In particular, the expertise and professionalism of its lawyers are impressive.’
‘The quality of service provided by Ning Liu’s team in this field has always been good and trustworthy.’
‘The team is highly professional and demonstrates particular strength in assisting clients with negotiations. Serious and dedicated attitude.’
‘Zoe Wang and Fangzhou Zhang are recommended.’
‘Ning Liu’s legal team provides legal services for many leading pharmaceutical and medical enterprises and well-known investment funds in the industry. One of its characteristics is to integrate and provide legal services for the whole industry chain, including daily operations, research and development, clinical trials, drug and medical device registration, FCPA compliance, privacy protection, mergers and acquisitions, minority equity investment and overseas capital markets.’
‘Ning Liu provides customised solutions and not only leads the team himself but also effectively integrates lawyers from other fields within JunHe to serve his clients. He is very sensitive about the client’s business needs and gives timely advice.’
‘The JunHe team possesses in-depth knowledge of the life science sector. They are able to provide services in a wide range of areas, including IP prosecution, Licence matters, collaboration agreements, joint ventures, outsourcing, M&A, debt and capital markets, etc.’
‘We particularly appreciate the timely and professional advice of Yun Shi.’
Goldman Sachs (Asia) L.L.C
Guangzhou Pharmaceutical Holdings Limited
Morgan Stanley Asia Limited
PAG Asia Capital (HK) Limited
Jiangsu Hengrui Medicines Co., Ltd
Tripod Preclinical Research Laboratories Co., Ltd
Hinova Pharmaceuticals Inc
China International Capital Corporation Limited(CICC)
Jiangsu China Life Jiequan Equity Investment Center (Limited Partnership)
- Advised BeiGene on its A-Share IPO on the SSE STAR Market, assisting it in becoming the first biotechnology company to be listed in Shanghai, Hong Kong and New York.
- Assisted Asymchem with its listing on the Main Board the Hong Kong Stock Exchange and its A+H share listing.
- Acted for HUTCHMED (China) on its listing on the Main Board of the Hong Kong Stock Exchange.
At Haiwen & Partners, the life sciences and healthcare team is particularly known for its strong expertise in transactional matters, often handling large cross-border M&A, IPOs, equity investments, and financings. In addition to its transactional strength, the group is well versed in data protection and privacy, complex collaboration agreements, antitrust, IP licensing and dispute resolution. Splitting her time between Beijing and Shanghai, Tina Wu, who is a key contact for licensing deals and M&A, overseas the practice. Hao Bian, Wenzhen Dai, Rui Feng and Ji Hu are recommended for transactional matters while Frank Wang and Hanguo Zhang focus on IP matters and disputes. In September 2021, the firm welcomed former King & Wood Mallesons' practitioner Yingqi Li boosting the team’s IP and litigation capabilities.
Other key lawyers:
Hao Bian; Wenzhen Dai; Rui Feng; Ji Hu; Yingqi Li; Frank Wang; Hanguo Zhang
‘Haiwen & Partners focuses on cross-border securities, M&A transactions, private equity, and general corporate practice. The team acted as our corporate legal counsel during my company’s successful IPO listing. They behaved professionally and provided valuable advice during the whole IPO application process.’
JP Morgan Securities (China) Co., Ltd
Shanxi Zhendong Pharmaceutical Co., Ltd
China International Capital Corporation Hong Kong Securities Limited|Morgan Stanley Asia Limited
Clarity Medical Group Holding Limited
Tsing Song Capital
Lilly Asia Ventures
Ali JK Medical Products Limited
- Acted for BeiGene on its listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange, with a total amount of funds raised of approximately ¥22.2bn.
- Advised Shanxi Zhendong Pharmaceutical Co., Ltd on its sale of 100% of its wholly-owned subsidiary Langdi Zhiyao to FountainVest Partners for ¥5.8bn.
- Assisted Lepu Biopharma Co., Ltd with its 18A listing on the Main Board of the Hong Kong Stock Exchange.
Founded in 2016, Shihui Partners focuses on private equity investment, capital markets and financial transactions, making it a popular choice for investment funds, PE and VC firms and companies seeking advice on transactions in the life sciences and healthcare industry, such as cross-border M&A and funding rounds. Xiangjun Kong, who has extensive experience in handling compliance projects, corporate financing and M&A for pharmaceutical and healthcare companies, overseas the group alongside Jing Lu and Xiaomei Li. Lu is recommended for data protection and licensing matters while Li is a key contact for investment transactions.
Xiangjun Kong; Jing Lu; Xiaomei Li
‘The life sciences and healthcare team at Shihui provides our company with year-round legal and project consulting services. With an in-depth knowledge of the industry and business-friendly advice, the team stands out among its competitors.’
‘The solutions proposed are always efficient and clear, providing in-house counsels with easy to implement advice.’
‘It is worth mentioning that the lawyer’s fees are very competitive and cost efficient.’
‘Xiangjun Kong not only provides professional and practical solutions , but also provides innovative ideas for addressing risks faced clients.’
‘Xiangjun Kong is very good at breaking down complex legal concepts and explaining them to clients in an easy and concise manner. He is a trusted partner and very professional.’
Huaxing Medical Industry Fund
Taiping Industry Investment Manage Co., Ltd
CCB International (Holdings) Co., Ltd
- Assisted Pfizer Inc in establishing a personal information protection compliance system.
- Advised Hanhui Pharmaceuticals Co., Ltd on its internal system building, business and compliance legal department compliance training, and business projects.
- Acted for Juventas Cell Therapy Ltd, a biomedical company focusing on the R&D and the commercialisation of innovative drugs such as immune cell therapy, on various matters, including development and cooperation projects and product registration.
Tian Yuan Law Firm
Tian Yuan Law Firm‘s Beijing-based team is noted for its broad life science and healthcare offering, which includes regulatory compliance, antitrust, IP, dispute resolution and anti-bribery, with a strong focus on M&A, overseas IPOs and investment transactions. The group’s leadership is split between Yixing Li and Juanjuan Song, who is especially sought after by state-owned companies, private equity firms and financial institutions to handle corporate investments and restructurings. Other key names include capital markets and IPO specialist Ping Xu, Xiaohui Zhu who is recommended for venture capital and private equity matters, and M&A expert Yan Liu.
Juanjuan Song; Yixing Li
Other key lawyers:
Ping Xu; Xiaohui Zhu; Yan Liu
- Assisted Gushengtang Holding Limited with its IPO in Hong Kong.
- Advised Yonghe Medical Group on its listing on the Main Board of the Hong Kong Stock Exchange.
- Acted for Acotec Scientific Holdings Limited on its successful listing on the Main Board of the Hong Kong Stock Exchange.
Jingtian & Gongcheng‘s life sciences and healthcare practice is particularly known for its track record in compliance matters, investment deals, IPOs and follow-on offerings as well as M&A. The group is jointly led by Boija Zhao, who advises private equity and venture capital houses on minority investments, and Hanshuo Zhou who is recommended for general corporate matters, licensing issues and product registration. Zhao and Zhou work alongside Yuanpeng Lang and capital markets expert Wei Ren.
Hanshuo Zhou; Boija Zhao
Other key lawyers:
Yuanpeng Lang; Wei Ren
MicroPort CardioFlow Medtech Corporation Sirnaomics Ltd
Yonghe Medical Group Co., Ltd
Conba Group & ZSM Pharma
OrbiMed Advisors LLC
China State-owned Enterprise Mixed Ownership Reform Fund Co., Ltd
Chong Yao Hui Sheng Healthcare Investment Fund (a sub-fund under the C.Q. Pharmaceutical Group)
China Meheco Group Co., Ltd
China General Technology (Group) Holding Co Ltd
China Merchants Capital
Taikang Insurance Group
Xiamen C&D Corporation
State Development & Investment Corp., Ltd. (SDIC)
Yonghe Medical Group Co., Ltd
Shenyang Xingqi Pharmaceutical Co., Ltd
Qiming Venture Partners
Deepwise Limited (DeepWise)
- Assisted Yonghe Medical Group Co., Ltd with its initial public offering and listing on the Main Board of the Hong Kong Stock Exchange.
- Acted on the Medlinker Group Companies and the Lifespace Group Companies’ merger.
- Advised MicroPort CardioFlow Medtech Corporation on its successful listing on the Main Board of the Hong Kong Stock Exchange.
Yuanda China Law Offices
Benefiting from a strategic alliance with Winston & Strawn LLP, Yuanda China Law Offices is well placed to assist domestic and multinational pharmaceutical and life sciences companies with cross-border matters. The practice’s offering covers a wide range of matters, including intellectual property and licensing transactions, M&A, joint ventures and regulatory compliance. The Shanghai-based team is led by James Jiang, who is recommended for government affairs, compliance matters and litigation. Jiang works alongside Jinhua Song, who has extensive experience in advising on PE and VCand M&A transactions.
Other key lawyers:
Shanghai Shyndec Pharmaceutical Co., Ltd
Guangzhou OncoImmune Biotechnology Co., Ltd
Qinhao Pharmaceutical (Suzhou) Co., Ltd
Beijing FORYOR Health Medical Technology
Yinchuan FORYOR Internet Hospital Co., Ltd
- Acted for Shyndec on its proposed acquisition of a majority stake in a company registered in Beijing.
- Assisted Beijing FORYOR Health Medical Technology in obtaining an internet hospital licence.
- Advised Qinhao Pharmaceutical (Suzhou) Co., Ltd on its several rounds of financing.